Showing 88 results
Archival description
E6 FDA Approves Volcanos iFR.pdf
E6 PSE global client list.pdf
![[E6] REF Impact evidence - RR - Technical Innovation in Blue Spot.bmp](/uploads/r/null/8/4/c/84c94aea964b952033b8ab5012f8289838b0e198fcaf1f656fcfe14f87a9e123/c1ac10a8-6d26-46e1-928c-a15331abb5f6-_E6__REF_Impact_evidence_-_RR_-_Technical_Innovation_in_Blue_Spot_142.jpg)
[E6] REF Impact evidence - RR - Technical Innovation in Blue Spot.bmp
E6 Thermo Fisher Scientific -annual reports 2014-2020.pdf
E6a DCRP_MP_19_02_Report to Authority - ENA EREP 130 Issue 3_final.pdf
E6b - ENA D-Code - ENA_EREP_130Issue 3(2019).pdf
E7 - Ceres-Power-Holdings-plc_Interim-Results-for-the-12mths_FINAL.pdf
E7 - Targeted NGS or Serology for SARS-CoV-2 Epidemiology Research.pdf
E7 Examples of gPROMS applications.pdf
E7 iFR Outcome Data Philips Healthcare.pdf
E7a GSK annual-report 2017.pdf
E7b GSK annual-report-2018.pdf
E7c GSK annual-report 2019.pdf
E8 - Ceres Power and Weichai Finalise Strategic Collaboration and JV Agreement.pdf
E8 - Sequencing of SARS CoV-2.pdf
E8 ESC_EACTS Guidelines.pdf
E8 Sensodyne - How marketing created a billion dollar brand.pdf
E9 - dnae-barda-funding_30sep16_dnae_v5-clean.pdf
E9 - market cap - Ceres Power 29 Jan 2021.pdf
E9 Appropriate Use Criteria article